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Abstract
Background: Mucosal levels of Secretory Leukocyte Protease Inhibitor (SLPI) are specifically reduced in relation to
H. pylori-induced gastritis. Progranulin is an epithelial growth factor that is proteolytically degraded into fragments
by elastase (the main target of SLPI). Considering the role of SLPI for regulating the activity of elastase, we studied
whether the H. pylori-induced reduction of SLPI and the resulting increase of elastase-derived activity would reduce
the Progranulin protein levels both ex vivo and in vitro.
Methods: The expression of Progranulin was studied in biopsies of H. pylori-positive, -negative and -eradicated
subjects as well as in the gastric tumor cell line AGS by ELISA, immunohistochemistry and real-time RT-PCR.
Results: H. pylori-infected subjects had about 2-fold increased antral Progranulin expression compared to
H. pylori-negative and -eradicated subjects (P < 0.05). Overall, no correlations between mucosal Progranulin and
SLPI levels were identified. Immunohistochemical analysis confirmed the upregulation of Progranulin in relation to
H. pylori infection; both epithelial and infiltrating immune cells contributed to the higher Progranulin expression
levels. The H. pylori-induced upregulation of Progranulin was verified in AGS cells infected by H. pylori. The
down-regulation of endogenous SLPI expression in AGS cells by siRNA methodology did not affect the Progranulin
expression independent of the infection by H. pylori.
Conclusions: Taken together, Progranulin was identified as novel molecule that is upregulated in context to
H. pylori infection. In contrast to other diseases, SLPI seems not to have a regulatory role for Progranulin in
H. pylori-mediated gastritis.
Background
Secretory leukocyte protease inhibitor (SLPI) is a mem-
ber of the chelonianin class of serine protease inhibitors,
and is predominantly expressed in secretory epithelial
cells of mucosal surfaces, immune cells and has been
identified in various tissues [1-3]. Among serine protei-
nase inhibitors, SLPI is considered as “alarm proteinase
inhibitor” that is upregulated during infection or inflam-
mation to compensate for high human neutrophil elas-
tase [1,4]. The C-terminus of SLPI primarily inhibits
human elastase, but is capable of inhibiting other serine
proteinases such as tryptase and cathepsin G [5]. In
addition to its function as an antiprotease, SLPI pos-
sesses antimicrobial activity against several bacteria and
fungi [1,4,6]. Furthermore, it was shown that SLPI con-
trols cell proliferation by regulation of growth-associated
genes such as cyclin D and transforming growth factor
(TGF)-b1 [7], modifies the activation of macrophages
[4] and regulates the LPS-induced activation of the tran-
scription factor “nuclear factor kappa B” (NF-B) [8,9].
SLPI-deficient mice provided evidence for functional
involvement of SLPI in wound healing [10] and lipopo-
lysaccharide (LPS)-mediated inflammation [11]. In con-
text to its role as “alarm proteinase inhibitor”, SLPI was
found to be differentially regulated in inflammatory dis-
eases and cancer. Increased expression or elevated
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experimental endotoxemia [12], febrile patients [13],
Wegners’s granulomatosis [14], gastric cancer [15] and
pulmonary infection [16]. In contrast, other bacterial or
viral infections in lung [17], stomach [18] and cervical
epithelial cells [19] were found to be associated with
decreased SLPI levels. The underlying mechanisms
responsible for the different regulation of SLPI have not
been identified, but most likely both microbial and host
factors contribute to the up- or downregulation of SLPI
in the various diseases. Notably, the reduction of SLPI
levels correlated inversely with the severity of inflamma-
tion (infiltration of granulocytes) and neutrophil elastase
activity in the gastric mucosa of H. pylori-infected indi-
viduals [20,21] and the bronchoalveolar lavage fluid
(BALF) of Pseudomonas-infected subjects [17].
Progranulin, also known as acrogranin, proepithelin
and PC cell derived-growth factor, is a 68 kDa glycopro-
tein secreted by many epithelial and immune cells [22].
The full-length protein is subsequently modified by lim-
ited proteolysis leading to the generation of 6-25 kDa
fragments called granulins [23]. Pathophysiologically,
Progranulin has drawn a lot of attention in the last
years since it has been identified that mutations of the
corresponding granulin gene are causally linked to the
development of frontotemporal dementia [24]. Indivi-
duals with these mutations exhibit tau-negative, but ubi-
quitin-positive, inclusions in their brain that eventually
cause frontotemporal dementia. Both the precursor
(Progranulin) and the degraded forms (Granulins) med-
iate different cellular effects in a variety of pathophysio-
logical conditions such as inflammation, proliferation,
carcinogenesis and wound healing [25]. While Progranu-
lin acts as growth factor for epithelial cells, fibroblasts
and neurons and has anti-inflammatory properties
[26,27], granulins drive inflammation leading to the
infiltration of immune cells and induced cytokine
expression [28,29]. The conversion of Progranulin to
granulins, which is the critical step in the regulation of
the balance between both molecular forms, is controlled
by SLPI that binds Progranulin and prevents degrada-
tion by elastase [23]. The importance of this interaction
for the wound healing was demonstrated at the SLPI-
deficient mice [10]. The lack of SLPI resulted in higher
serine protease-derived activities that were associated
with impaired wound healing in these animals [10]. The
delayed wound healing was normalized after the addi-
tion of Progranulin providing evidence for the impor-
tance of the interaction between Progranulin and SLPI.
We recently identified a marked down-regulation of
mucosal SLPI levels in H. pylori-infected subjects [18].
The role of SLPI for the balance between Progranulin
and granulins and the high prevalence of mucosal inju-
ries (ulcer, erosions) in H. pylori-infected subjects,
prompted us to study the expression levels of Progranulin
in context to that of SLPI in relation to H. pylori status.
Considering the role of SLPI for regulating the activity of
elastase, we hypothesized that the H. pylori-induced reduc-
tion of SLPI would lead to a reduction of mucosal Progra-
nulin levels, since the higher elastase activities in the
mucosa of H. pylori-infected subjects would degrade the
molecule into the granulin fragments. In addition, gastric
epithelial cells (either infected with H. pylori ± transfection
of SLPI-siRNA) were used as in vitro model to prove the
proposed hypothesis.
Methods
Study design and H. pylori status
The study protocol was conducted according to the
declaration of Helsinki and approved by the ethics’ com-
mittee of the Otto-von-Guericke University (No. of ethi-
cal vote: 143/99) as well as government authorities; all
participants signed informed consent before entering the
study. Details of the protocol (inclusion, exclusion cri-
teria, and demographic data) were described previously
[20]. The initial protocol was aimed at studying the
interaction of H. pylori infection and low-dose aspirin.
Briefly, human healthy volunteers were stratified accord-
ing to the H. pylori status leading to the H. pylori-posi-
tive (H. pylori
+,n=1 0 )a n d- n e g a t i v e( H. pylori
-,n=
10) group. After successful eradication therapy, 9 out of
10 H. pylori-infected individuals agreed to participate in
this study after 3 months again composing the
H. pylori-eradicated (H. pylori
erad) group. In order to
investigate the potential interaction between Progranulin
and SLPI, mucosal and serum levels as well as gene
expression levels of Progranulin were analyzed retro-
spectively in existing samples and tissue specimens in
relation to H. pylori status and SLPI expression levels
published previously [20]. The analysis of Progranulin
expression was performed in the “pre-treatment” sam-
ples, which correspond to day 0 [20] before “low-dose”
aspirin was taken by the individuals.
The study includes a correlation analysis of mucosal
Progranulin levels with those of SLPI studied in the
same cohorts previously; details concerning the analysis
of SLPI were reported recently [20].
Determination of Progranulin expression quantitative
RT-PCR and ELISA
Progranulin levels were quantified in the total protein
extract from mucosal biopsies at sera stored at -80°C in
previous study [22]. Progranulin levels were quantified
using the Progranulin ELISA kit (Axxora GmbH, Lör-
rach, Germany; No: AG-45A-0018PP-KI01) as described
by the manufacturer. Protein levels were normalized
to ng/μg total protein content of extracted mucosal
samples or ng/ml for sera.
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mined by quantitative RT-PCR using existing cDNA
samples stored at -80°C. Quantitative RT-PCR was per-
formed using an iCycler (BioRad, Munich, Germany) and
HotStarTaq Master Mix™ (Qiagen, Hilden, Germany) as
described [23]. Initial activation of Taq-polymerase at
95°C for 15 min was followed by 40 cycles with dena-
turation at 94°C for 30 s, annealing at 60°C for 30 s and
elongation at 72°C for 30 s. The fluorescence intensity
of the double-strand specific SYBR-Green I, reflecting
the amount of actually formed PCR-product, was read
real-time at the end of each elongation step. Then spe-
cific initial template mRNA amounts were calculated by
determining the time point at which the linear increase
of sample PCR product started, relative to the corre-
sponding points of a standard curve; these are given as
arbitrary units (a.u.). Both PCR products were cloned
into the pDIRECT™ (Qiagen, Hilden, Germany), and
subsequent dilutions of the corresponding plasmid
DNA were used to create a standard curve for the RT-
PCR. The correlation coefficients of both Progranulin
and b-actin standards were > 0.95. b-actin mRNA
amounts were used to normalize the cDNA contents of
the different samples. Final data reflect the ratio in a.u.
between Progranulin transcript and b-actin transcript
levels. The following primers were used for the RT-PCR
analysis: ß-actin (fw:5’-GCC-ATC-CTG-CGT-CTG-
GAC-C-3’ rev: 5’-ACA-TGG-TGG-TGC-CGC-CAG-
ACA-G-3’; 400 bp), and Progranulin (fw:5`-ATG-GCC-
CAC-AAC-ACT-GAG-CAG-G-3`, rev: 5`-TCT-GGG-
CAG-GGA-GCT-TCT-TTG-C-3`, 440 bp). Both cDNA
fragments included intron-spanning regions resulting in
the generation of a larger PCR product from genomic
DNA or its exclusion. Therefore, all identified PCR pro-
ducts can exclusively be attributed to the mRNA pool
of the sample.
Immunohistochemical analysis of Progranulin expression
in the gastric mucosa
To study the cellular origin of Progranulin expression in
antral and corpus mucosa, tissue specimens from all 29
individuals were subjected to immunohistochemical ana-
lysis. The pathologist (D.K.) was blinded to the group
assignment of samples. Paraffin-embedded biopsy speci-
mens were cut into 3 μm thick sections, mounted on
glass slides, and treated with Xylol and dehydrated by
standard protocols. For antigen retrieval, specimens
were boiled three times in 0.01 M sodium citrate puffer
(pH 6.0) for 10 min in a microwave (600W). Incubation
with primary polyclonal goat-derived anti-Progranulin
antibody (BAF2420, dilution 1:1.000, R&D Systems,
Minneapolis, MN, USA) was conducted at 37°C for
35 min and followed by PBS-washing. Positive immunohis-
tochemical reactions were revealed using the iVIEWTM
DAB Detection Kit (Ventana, Germany) as chromogen
substrate. Finally, the samples were counter-stained with
hematoxilin, dehydrated and mounted using DEPEX
(Serva, Heidelberg, Germany). For positive control normal
prostate tissue was used. For negative control correspond-
ing stainings were performed using unrelated goat
a n t i s e r u mt h a td i dn o tl e a dt oas p e c i f i cs t a i n i n g( d a t a
not shown).
Expression of Progranulin was scored for the epithe-
lium of the mucosal surface and gastric glands of the
antrum and corpus in 3 representative high power fields
(Zeiss Axioskop 50). Staining intensity (SI) and the per-
centage of positive cells (PP) were assessed using the
following semiquantitative score: SI was classified in 0
(no staining), 1 (weak), 2 (moderate) and 3 (strong); PP:
0 (no positive cells), 1 (< 10%), 2 (10-50%), 3 (51 - 80%),
4 (> 80%). For each slide the immunoreactive score
(IRS) was calculated as [SI x PP] with a possible maxi-
mum score of 12. Immunohistochemical expression of
Progranulin was separately scored for surface epithelium
and glands, and then these scores were summarized as
“total score” that were statistically analyzed among the
three groups. The maximum score for epithelial expres-
sion of Progranulin was “24”. Since all type of immune
cells showed constantly strong expression of Progranu-
lin, only the number of these infiltrating cells was semi-
quantitatively assessed. Progranulin-immunoreactive
immune cells were evaluated for their quantity in the
lamina propria (1 = few, 2 = moderate, 3 = abundant).
Therefore, the maximum score of immune cell-related
expression of Progranulin was “3”.
Cell Culture and in vitro studies
AGS (CRL-1739) gastric cancer cells were purchased
from American Type Culture Collection (ATCC). Cells
were maintained in 25 cm
2 cell culture flasks (NUNC
GmbH, Wiesbaden, Germany) in a cell incubator at 37°
Ca n d5 %C O 2 using RPMI-1640 containing 10% FCS,
100 U/ml Penicillin, 100 μg/ml streptomycin and 100
μg/ml gentamycin (all reagents; PAA, Colbe, Germany).
Infection studies were performed using wildtype
H. pylori strain purchased from ATCC (No. 43504).
H. pylori was cultivated on selective agar plates (bioMer-
ieux, Marcy I’Etoile, France) under microaerophilic condi-
tions at 37°C for 2 days, and then resuspended in PBS (pH
7.4). Bacterial suspensions were adjusted based on optical
density at 535 nm (OD = 1 corresponds to 1 × 10
9 bac-
teria). To ensure functional active bacteria, suspensions
were microscopically inspected for shape and motility. After
washing cells twice with medium without FCS and antibio-
tics, cells were infected with H. pylori at a “multiplicity of
infection” of 50 in medium lacking antibiotics for 24 h.
For siRNA transfection, 4 × 10
5 cells were seeded
in complete medium in 6-well plates and cultivated for
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(No: S100726383) or All-Stars™ negative siRNA control
at a final concentration of 3 nM using HiPerfect™
transfect reagent as described by the manufacturer (all
reagents, siRNA from Qiagen). Cells were cultivated in
the presence of siRNA for another 48 hours at standard
conditions, and then infected with H. pylori as described
above.
After completing transfection and/or infection experi-
ments, 0.8 ml of the cell culture medium was collected,
centrifuged at 8.000 × g, and the supernatant stored in
aliquots at -80°C for analysis. AGS cells were washed
three-times with PBS (pH 7.4), and then harvested by
PBS (pH 7.4) using a cell-scraper. Cells were washed
once (8.000 × g, 4°C, 15 min) and resuspended in 1 ml
PBS (pH 7.4). The sample was aliquoted (2 × 500 μl)
into two Eppendorf tubes™ (Eppendorf AG, Hamburg,
Germany), cells were obtained by centrifugation and the
resulting pellets were stored at -80°C until analysis.
Three individual experiments (each as duplicate) were
performed for all experiments settings.
Statistical Analysis
All data were entered into a database using the Microcal
Origin™ 8.0G program package (Northhampton, MA,
USA). Data are expressed as raw, median, mean ± standard
deviations error (SD), or 95% CI (confidence intervals), if
not stated otherwise. Non-parametric Kruskal-Wallis test
and Mann-Whitney U test were applied for multiple and
pairwise comparisons between groups, respectively. Immu-
nohistochemical data were analyzed by One-way ANOVA
(as global test for multiple testing) and LSD as post hoc
analysis for pairwise comparisons if global test reached sig-
nificant level. Correlation analysis was performed by Pear-
son test. All test were applied two-sided with a level of
significance of P < 0.05.
Results
Expression of Progranulin in gastric mucosa in relation to
H. pylori status and SLPI levels
Progranulin gene expression and corresponding protein
levels were identified in all mucosal samples from
antrum and corpus as well as serum levels. As shown in
figure 1, protein levels demonstrated normal distribu-
tion, while gene expression levels revealed skewed distri-
bution. Therefore, we decided to apply nonparametric
tests for both methodologies.
H. pylori-infected subjects had about 2-fold higher Pro-
granulin protein levels (median: 0.43, range: 0.33-0.63 ng/μg
protein) compared to levels after the successful eradica-
tion (median: 0.25, range: 0.25-0.46 ng/μg protein) or the
unrelated H. pylori-negative group (median: 0.34, range:
0.27-0.46 ng/μg protein; p < 0.05) (Figure 1, upper
panel). Progranulin protein levels in corpus mucosa
(medians: 0.19 - 0.26 ng/μg) and serum samples (med-
ians: 173 - 206 ng/ml) did not differ among the three
groups (Figure 1, upper panel). Progranulin-mRNA
amounts differed significantly in antrum among the three
groups. As illustrated in figure 1 (lower panel), H. pylori-
negative subjects revealed highest transcript amounts
(median: 0.38, range: 0.2-1.3 a.u.), followed by the
H. pylori-positive subjects (median: 0.17, range: 0.02-0.58
a.u.), and were lowest after eradication (median: 0.06,
range: 0.03-0.07 a.u.). Similar results were obtained for
corpus mucosa without reaching significance (Figure 1,
lower panel).
To investigate a potential association between mucosal
Progranulin and SLPI levels, correlation analysis was
performed between both parameters. Please note that
data concerning SLPI expression in these cohorts were
published previously; therefore these data are not shown
in detail in this study [20]. As illustrated in figure 2,
a significant positive correlation was identified in
Figure 1 Progranulin levels in gastric mucosa and serum in
relation to H. pylori-status. Data were stratified to location
(antrum, corpus, serum) and H. pylori status as indicated by the
legend and X-axes. Boxes represent the 25th, 50th and 75th
percentile values (horizontal lines of the box) and means (squares).
Significant differences were identified by Kruskal-Wallis (for multiple
groups) and Mann-Whitney U test (pairwise comparisons) for
antrum only; corresponding P-values are shown.
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both other groups as well as in the combined data set.
No correlations between Progranulin and SLPI were
identified in corpus mucosa and serum of the three indi-
vidual groups (data not shown).
Immunohistochemical localization of Progranulin in the
gastric mucosa
As illustrated in figure 3, both epithelial and infiltrating
immune cells contribute to the mucosal Progranulin
expression. Immune cells (granulocytes, lymphocytes)
showed constantly high expression of Progranulin except
cells of lymphoid follicles. Higher numbers of Progranu-
lin-expressing cells were associated with gastritis in H.
pylori-infected subjects (Figure 3A+D). For the epithelium,
strongest expression was observed in the gastric glands
followed by the basis of the foveolae mainly in areas of
dense inflammatory infiltrate. Surface epithelium between
gastric pits showed weak or no expression of Progranulin.
Semiquantitative scoring revealed significant higher
expression scores of Progranulin for H. pylori-infected
subjects compared to both other groups in antrum
(Figure 4, left panel), whereas a tendency was observed for
corpus (Figure 4, right panel). Furthermore, the number of
infiltrating Progranulin-expressing immune cells was
significantly higher in both antral and corpus mucosa of
H. pylori-infected subjects (Figure 4).
Expression of Progranulin and SLPI in epithelial AGS cells
infected by H. pylori
To investigate the regulatory link between SLPI and
Progranulin, both molecules were investigated in rela-
tion to H. pylori infection and siRNA-mediated downre-
gulation of SLPI expression in AGS cells. As
demonstrated in figure 5, cellular SLPI levels were sig-
nificantly reduced by 33%, 63%, and 81.3% by H. pylori,
siRNA, and both factors, respectively. SLPI levels in the
supernatant were strongly reduced (-65%) by siRNA, but
not by H. pylori (Figure 5). The analysis of Progranulin
levels in the identical samples, revealed no effect of
SLPIsiRNA treatment. Both cellular (94.7 ± 9.4%) as
well as secreted (109.4 ± 3.3%) Progranulin levels were
Figure 2 Correlation analyses between antral levels of SLPI (Y-axes) and Progranulin (X-axes). Three groups and the combined analysis
are indicated in the figure. Each dot represents one proband. Significant correlation and a non-significant trend (one outlier, marked with a
cross) were observed for H. pylori-eradicated and - positive group.
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Page 5 of 9Figure 3 Immunohistochemical detection of Progranulin in gastric antral mucosa. Immunohistochemical stainings exemplarily illustrate
Progranulin expression in biopsies from gastric mucosa of the antrum and corpus, respectively, of H. pylori-positive (A+D), -eradicated (B+E) and
-negative (C+F) subjects as identified in figure. Expression was seen in a granular pattern evenly distributed to the epithelial cytoplasm of the
glands and crypts and accentuated to the base of the surface epithelium. Enlargements of panel A+D demonstrate the Progranulin-expressing
immune cells (mostly granulocytes) in the mucosa of an infected individual, whereas these cells are less abundant in corresponding samples of
H. pylori-eradicated (panel B+E) and -negative individuals (panel C+F). Microscope: Zeiss Axioscope 50, camera: Nikon coolpix 990; enlargements:
×100, ×400.
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ciated with elevated Progranulin level in supernatant
(353 ± 109%), while cellular levels were found to be
slightly reduced (70 ± 5.9%, P < 0.05). The combined
effect of H. pylori and SLPI-siRNA approach resulted in
similar changes (331 ± 97% and 61.3 ± 8.9% of Progra-
nulin levels in supernatant and lysate, respectively (P <
0.05, Figure 5).
Discussion
Here we demonstrate that (I) the H. pylori infection is
associated with increased Progranulin levels in the antrum
of infected subjects, and (II) that both epithelial and infil-
trating immune cells contribute to this phenomenon.
Furthermore, we provided evidence that (III) the upregula-
tion of Progranulin seems to be independent of SLPI
levels. Considering the central role of the elastase/SLPI
equilibrium for the conversion of Progranulin to granulins
[10] and the previously identified deregulation of elastase/
SLPI expression in H. pylori-induced gastritis [21], we
anticipated a negative correlation between SLPI and Pro-
granulin for this disease. The H. pylori-induced reduction
of mucosal SLPI levels resulted in higher elastase activities
that were expected to degrade Progranulin leading subse-
quently to diminished mucosal Progranulin levels. In con-
trast to our working hypothesis (we expected a negative
correlation between mucosal SLPI and Progranulin levels),
we identified an increase of mucosal Progranulin levels in
the antrum of H. pylori-infected subjects. Furthermore,
correlation analyses revealed rather a trend or even a posi-
tive correlation between both proteins implying that the
proposed regulatory link between SLPI and Progranulin is
not present in this disease.
The fact that increased Progranulin levels were mostly
restricted to antral mucosa (except immunohistochem-
ical score of corpus glands) suggests an association of
this upregulation with the degree of gastritis. As pre-
viously demonstrated, all probands presented antrum-
predominant gastritis that was associated with moderate
and severe activity scores reflecting the number of infil-
trating granulocytes and lymphocytes [20]. As shown in
immunohistochemical stainings of the study, immune
cells were strongly positive for Progranulin and represent
a major source of mucosal Progranulin levels in addition
to gastric epithelial cells. Collectively, data of immunohis-
tochemistry correspond to quantitative assessment of
Progranulin by ELISA supporting the identified upregula-
tion of Progranulin in H. pylori-infection.
Interestingly, H. pylori-negative subjects revealed sig-
nificant higher progranulin transcript levels, which were
associated with lower protein levels, compared to those
of the H. pylori-positive and -eradicated group. The
missing concordance between transcriptional and pro-
tein level is not easily explained and remains unclear.
One potential explanation might be different regulatory
mechanisms of Progranulin expression in gastric epithe-
lial cells of H. pylori-negative subjects, who have been
negative for the complete life compared to individuals
after successful eradication therapy being without
Figure 4 Semiquantitative analysis of Progranulin expression in
gastric mucosa. Data illustrate semiquantitative immunoreactive
scores (mean ± standard deviation) of Progranulin expression for
gastric epithelium and immune cells (antrum: left panel; corpus
right panel). Note that maximal scores are 24 and 3 for gastric
epithelium and immune cells, respectively. The presence of
significantly different scores among the three groups was
performed by ANOVA test; significant differences are marked by “#”.
Figure 5 Expression of Progranulin in relation to SLPI and H.
pylori in AGS cells. AGS cells were treated as indicated in the
legend and explained in the section “Material and Methods”. Data
present relative values of 3 individual experiments (each with
duplicates). SLPI and Progranulin levels were quantified by ELISA;
control values (100%) were for SLPI: 64.3 ± 15.2 pg/50 μg and 452.4
± 116.4 pg/ml and Progranulin 1.2 ± 0.09 ng/50 μg and 0.36 ± 0.1
ng/ml. Control transfection experiments using “all-star-negative"™
siRNA (Qiagen) as negative control showed a reduction of SLPI
levels to 82.1 ± 6.3% and 82.3 ± 19.2% for lysate and supernatant,
respectively (n = 3, each duplicates). Cells were transfected with
siRNA, infected with H. pylori after 48 h and harvested after 72 h.
Asteriks (*) illustrate significant changes in relation to corresponding
control (two-sided paired T test, P < 0.05). Global test for multiple
groups (ANOVA) was significant for all four groups (P < 0.05).
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recently for mucosal infiltration and by the numbers of
Progranulin-expressing immune cells in this study, sam-
ples from patients after eradication therapy contained
still lymphocytes leading to slightly higher chronicity
scores [20] or slightly increased Progranulin scores com-
pared to H. pylori-negative subjects. Since in H. pylori-
positive subjects, two major Progranulin-expressing cell
types (epithelial and immune cells) are simultaneously
present, Progranulin transcript levels can not be
assessed individually for each cell type. Despite the miss-
ing concordance between protein and transcript levels, it
should be emphasized that the mucosal levels of Progra-
nulin were found to be significantly upregulated in
H. pylori-infected subjects.
The results obtained in the AGS cell model do par-
tially not correspond to the ex vivo findings. While ex
vivo data demonstrated an upregulation of Progranulin
by H. pylori, in the AGS cell model, only the concentra-
tion of Progranulin in the supernatant was strongly
induced, whereas the cellular expression, analyzed in the
lysate, was decreased. There are several aspects that
might explain these disconcordant results. In AGS cells,
both the intracellular and secreted proportion of Progra-
nulin was separately analyzed. Since in ex vivo analysis,
both compartments can not be differentiated, the
increased Progranulin levels in antral mucosa might
reflect both increased secretion and changes in epithelial
Progranulin expression. Second, ex vivo analysis is per-
formed on complex samples including epithelial and
immune cells, whereas the in vitro model only mirrors
the direct interaction of H. pylori to epithelial-derived
A G Sc e l l s .T h i r d ,a n a l y z i n gthe Progranulin expression
after 24 hours represents the effects of an acute infec-
tion, whereas changes in mucosal biopsies can be con-
sidered as long-term effects of an chronic infection that
are in a “steady-state”. Despite these limitations, data
from the in vitro model allow the conclusion that a
down-regulation of epithelial SLPI expression (either by
H. pylori or siRNA) does not affect the expression of
Progranulin in AGS cells. Owing to the low molecular
weight of granulins, no method is currently suitable to
analyze quantitatively the levels of the Progranulin-
derived degradation products. Therefore, no statement
can be made concerning the equilibrium between Pro-
granulin and granulins in gastric mucosa that might
hypothetically be shifted towards granulins even the
Progranulin levels are upregulated. Furthermore, it is of
note that SLPI is not the only serine protease inhibitor
expressed in the gastric mucosa. Recently, we identified
elevated alpha-1 protease inhibitor (A1-PI) levels in the
mucosa of H. pylori-infected individuals [30]. Since A1-PI
can inhibit elastase to a similar extent as SLPI [7], a com-
pensatory mechanism is another potential explanation,
while Progranulin is elevated, although SLPI levels are
strongly diminished in relation to H. pylori infection.
The observed association of induced Progranulin levels
in context to H. pylori infection and its associated gastritis
does not allow functional conclusions whether the upregu-
lation has an active regulatory role for the inflammatory
process, or it merely reflects the inflammatory conditions
of the underlying gastritis. Keeping in mind that Progranu-
lin acts as epithelial growth factor in other diseases [28,29],
it is tempting to speculate that the upregulation of Progra-
nulin in H. pylori-associated gastritis might be involved in
mucosal healing of gastric erosions/ulcers induced by this
infection. But at this moment, this remains purely specula-
tive since no functional data are available.
Conclusions
Taken together data from in vitro and ex vivo analysis,
we can conclude that the proposed regulatory link
between SLPI and Progranulin expression seems to be
of no or low relevance in context to the H. pylori infec-
tion. Furthermore, we provide evidence that Progranulin
is another molecule the expression of which is upregu-
lated in relation to this infection.
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